BeOne Medicines and InSysBio Partnership: Enhancing Oncology Trial Design and Risk Management

BeOne Medicines has extended its collaboration with InSysBio to refine clinical trial design for its oncology programs. The partnership focuses on applying mechanistic translational modeling to inform dosing regimens and address safety concerns such as cytokine release syndrome. This move aims to clarify dose selection and safety questions earlier in development, which can be important for patient protection and keeping studies on track. The partnership will support BeOne Medicines' drug development programs and inform future trial planning.